Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Relief of Nasal Congestion Associated With Seasonal Allergic Rhinitis (SAR)

Next Previous
Trial Profile

Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Relief of Nasal Congestion Associated With Seasonal Allergic Rhinitis (SAR)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mometasone (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Organon; Schering-Plough

Most Recent Events

  • 01 Mar 2010 Pooled results of this and an identically designed trial presented at the 66th Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) held on 26 Feb - 2 Mar 2010, in New Orleans, Los Angeles, USA.
  • 18 Nov 2009 Actual patient number (351) added as reported by ClinicalTrials.gov.
  • 07 Dec 2008 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top